Physiologists & the FDA Kevin J. Greenlees, Ph.D., DABT Senior Advisor for Science & Policy Office of New Animal Drug Evaluation FDA Center for Veterinary.

Slides:



Advertisements
Similar presentations
ICH Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Overview and Update Robert H. King, Sr. Office of Pharmaceutical.
Advertisements

The Fellowships aim to: Educate scientists and engineers on the intricacies of federal policymaking Provide scientific and technical knowledge to support.
Meg Oeller, DVM FDA Center for Veterinary Medicine 1.
Merton V. Smith, Ph.D., J.D. Director International Programs Center for Veterinary Medicine U.S. Food and Drug Administration Governance of Veterinary.
Dr. Michael E. Oehlsen International Policy Analyst International Programs Team - Office of the Director Center for Veterinary Medicine Food and Drug Administration.
The United States Experience Implementing the WTO SPS Agreement Hangzhou, China December 2008 Roseanne Freese Senior WTO SPS Affairs Officer United States.
WHAT IS A RESEARCH ETHICS BOARD?
International Standards for Food Quality and Safety – Accomplishments of the Codex Alimentarius Commission International Symposium on Food Safety Standards.
What’s New in the FDA’s Pharmaceutical Inspectorate and Risk Based Systems Inspection Rick Perlman Chair Food, Drug, and Cosmetic Division ASQ.
Regulation and Safety Assessment of Novel Foods in Canada William Yan, Ph.D. Office of Food Biotechnology Health Canada.
What Do Toxicologists Do?
FDA’s Pharmaceutical Inspectorate Robert Coleman National Expert Drug Investigator Food and Drug Administration.
Interagency Oncology Task Force (IOTF) Research and Regulatory Review Fellowships
Presentation 4.2 CODEX STANDARDS ON SAFETY Section IV Food Quality and Standards Service (ESNS) Food and Nutrition Division. FAO.
Ohio Nano-Summit March 3, 2005 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D. Associate.
Animal Feed GRAS Notifications Geoffrey K. Wong, M.S. Division of Animal Feeds Center for Veterinary Medicine Pet Food Institute Pet Food Institute October.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.
FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.
Protecting and Promoting Your Health How this work supports FDA’s mission: TO PROMOTE HUMAN and ANIMAL HEALTH by collaborating with veterinary diagnostic.
Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.
INTRODUCTION TO RA.
Enhancing International Capacity to Meet SPS Standards Mo Salman Animal Population Health Institute College of Veterinary Medicine and Biomedical Sciences.
C-059-I0 EVET C-061-I0 DVEFVMPVLM A-041-N0 B-004-H0 AORTA D-115-G0 C-068-I0 UP- DMHTE.
Developing responsible and ethical laboratory animal care and use programs which benefit the well being of animals while mutually working together with.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
“History is a set of lies agreed upon.” Napoleon Bonaparte.
*The views expressed in this presentation are those of the presenter’s and do not necessarily represent the views of the U.S. Food and Drug Administration.
Briefing by Department of Health to joint meeting of the Portfolio Committees on Agriculture, Forestry and Fisheries, Health, Trade and Industry, Rural.
Drug Transfer Into Breast Milk and Interpretation of Data Lawrence J. Lesko Office of Clinical Pharmacology and Biopharmaceutics Center for Drug Evaluation.
FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS Statistics Related to Food Safety and Quality Food and Nutrition Division. FAO.
FAO/WHO Codex Training Package Module 4.2 JOINT FAO/WHO CODEX TRAINING PACKAGE MODULE FOUR – SCIENTIFIC BASIS FOR CODEX WORK 4.2 Requesting, accessing.
Celeste F. Bové, M.A., CCC-A Senior Science Policy Analyst Office of Science Coordination & Communication Food and Drug Administration FDA Participation.
1 U.S. Food and Drug Administration International Programs Melinda K. Plaisier Assistant Commissioner for International Programs U.S. Food and Drug Administration.
FAO/WHO Codex Training Package Module 4.3 FAO/WHO CODEX TRAINING PACKAGE SECTION FOUR – SCIENTIFIC BASIS FOR CODEX WORK 4.3 What is JECFA?
Food Safety – Challenges, Problems, and Opportunities By Thomas J. Billy, President International Food Safety Consulting, LLC Former Senior U.S. Food Safety.
AAHRPP ACCREDITATION (Association for the Accreditation of Human Protection Programs)
Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.
FDA Public Meeting Preparation for the ICH Meetings in Tokyo, Japan, Including Progress on the Common Technical Document and Possibilities for New Topics.
JOINT FAO/IAEA PROGRAMME of Nuclear Techniques in Food and Agriculture 1 Sanitary and Phytosanitary Measures (SPS) Technical Barriers to Trade (TBT) &
1 Estimating CDER Resources Devoted to Safety Theresa M. Mullin, Ph.D. Office of Planning, Office of Commissioner April 15, 2005 Presentation to: FDA Science.
Veterinary Laboratory Investigation and Response Network Renate Reimschuessel 1, Sarah Nemser 1, Andriy Tkachenko 1, Olgica Ceric 1, Jake Guag 1, David.
Animal Drug Import Tolerances Under ADAA of 1996 FDA’s Public Health Protection, International Harmonization, and Trade-Related Goals Merton V. Smith,
The TJU Human Research Protection Program (HRPP): Part I – Which Entities/Offices are Involved ? J. Bruce Smith, MD, CIP.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Suzanne Sechen, Ph.D. Leader, Ruminant Drugs Team Division of Production Drugs Office of New Animal Drug Evaluation, CVM Labeling Issues.
INTERNATIONAL SCIENCE AND ENGINEERING FAIR Rules and Guidelines 2016.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.
Integrating the Life Sciences from Molecule to Organism The American Physiological Society Conscious Choice and Serendipity in Your Career Trajectory:
The CDRH Software Message (October 19, 2002) John F Murray Jr.. Center for Devices & Radiological Health US Food and Drug Administration
VICH General Principles and current update of VICH Outreach Forum activity 1.
-What is VICH, History and Objectives Hervé MARION, DVM VICH Secretariat.
1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.
The Benefits of VICH to VICH Member Countries and Regions DONALD A. PRATER, DVM Director, U.S. FDA Europe Office Office of International Programs Office.
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
. Lilly Diabetes Company Confidential Copyright© 2008 Eli Lilly and Company Company Confidential Copyright© 2008 Eli Lilly and Company Career Opportunities.
1 The contribution of VICH to the global One Health approach VICH5 CONFERENCE, OCTOBER 2015, TOKYO Jean-Pierre Orand, Anses, France, OIE Collaborating.
Who Are We? A Forum of Stakeholders Who Come together to Develop Science-based Solutions.
OIE Veterinary Legislation Support Programme: actions and perspectives - State of Kuwait Case study Dr. Abdul Rahman Al Kandari Director of Animal Health.
Interagency Oncology Task Force (IOTF)
Careers in Chemistry.
Office of Animal Welfare Assurance (OAWA) Janna Barcelo, BA, CPIA
VICH General Principles and
AGRICULTURAL & VETERINARY CHEMICALS REGULATION IN AUSTRALIA
Beyond Academia.
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Care of Research Animals
Pyatigorskaya Nataliya Valeryevna
Approach: The Cuban Regulatory Strategy
Presentation transcript:

Physiologists & the FDA Kevin J. Greenlees, Ph.D., DABT Senior Advisor for Science & Policy Office of New Animal Drug Evaluation FDA Center for Veterinary Medicine April, 2010

So Where Are the Physiologists...

Evaluate data submitted by pharmaceutical sponsors to demonstrate their veterinary drug (or additive for the animal food) is safe and effective Present evaluations to pharmaceutical sponsors and, when appropriate, negotiate approaches to address Agency concerns Comb publications, internet, presentations, professional meetings, and more to provide surveillance on the use of approved drugs and of unapproved drugs Direct regulatory legal actions (compliance) in cooperation with Federal and State prosecuters, investigators, and others. National and International meeting participation Participate in international efforts in harmonization for veterinary products Research What Do They Actually DO at CVM...

There are a number of ways I could talk about a physiologist’s role – I am going to tell you about some of the things I have done – since you won’t get a more physiologist’s eye view than that One Physiologist’s FDA Experience

A mentor in science is important - Dr. Alan Tucker One Physiologist’s FDA Experience Getting There

BS in Biology at SUNY Cortland MS in pulmonary physiology at Wright State University PhD in cardio-pulmonary physiology at Colorado State University One Physiologist’s FDA Experience

Post Doc at the University of Guelph, Canada Post Doc at the Virginia-Maryland Regional College of Veterinary Medicine at Virginia Tech One Physiologist’s FDA Experience

Physiologist in the Division of Residue and Manufacturing Chemistry Responsible for review and evaluation of residue data for new animal drugs in food producing animals Toxicologist in the Division of Toxicology and Environmental Sciences Responsible for review and evaluation of toxicology studies to support establishing an acceptable daily intake for residues of the veterinary drug in the human diet One Physiologist’s FDA Experience

Work as a regulatory review scientist is stimulating and NOT boring There are many more opportunities if you want more… One Physiologist’s FDA Experience

Project officer for contracts & grants for university research on total residue and metabolism of selected drugs in food fish Reviewer for the first approval of a beta-adrenergic agonist in food producing species Participated in risk assessment for clone food producing animals Reviewer for the first approved genetically engineered animal (goats producing rHuman Antithrombin in milk for human medicine) Co-Chair of the US Joint Subcommittee on Aquaculture Working Group on Aquaculture Drugs, Biologics, and Pesticides. One Physiologist’s FDA Experience

Expert and member of the United Nations FAO/WHO Joint Expert Committee on Food Additives in evaluation of residues of veterinary drugs Current US Delegate to the United Nations Codex Alimentarius Committee for Residues of Veterinary Drugs in Food, setting standards for residues in international trade. Chair of Safety Working Group for the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products One Physiologist’s FDA Experience

Physiology provides an exceptionally solid basis for this work at the FDA Center for Veterinary Medicine In the era of the NAS New Biology for the 21 st Century, physiology critically compliments the expertise of chemists, pharmacologists, nutritionists,animal scientists, veterinarians, and molecular biologists One Physiologist’s FDA Experience

I currently serve as a Senior Advisor for Science and Policy in the Office of New Animal Drug Evaluation. I am responsible for assuring that the Office maintains the highest standards of science, assist in solving problems in science and help in the interaction between science, laws and regulations (policy). I continue to meet and engage outstanding scientists in CVM, across the USG, in industry and academics, and internationally. One Physiologist’s FDA Experience

I draw on my training in physiology daily. The demands of regulatory review science are unique - but physiology provides a valuable and flexible scientific background to meet the mission of the FDA One Physiologist’s FDA Experience

Kevin J. Greenlees, Ph.D., DABT Senior Advisor for Science & Policy Office of New Animal Drug Evaluation FDA Center for Veterinary Medicine HFV-100, 7500 Standish Place Rockville, MD USA PH FX Thank you.